Impact of self-measurement of blood glucose on complications of type 2 diabetes: Economic analysis from a Czech perspectiveEconomic analysis of SMBG impact in the Czech Republic

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 289-296

  Weber, Christian ^a   Kocher, Serge ^a   Neeser, Kurt ^a   Bartaskova, Dagmar ^b  

^a Institute for Medical Informatics and Biostatistics   (Switzerland)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Diabetes complications; Diabetes mellitus; Healthcare costs; Matched pair analysis; Self measurement of blood glucose

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BUDGET; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CZECH REPUBLIC; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HEART INFARCTION; HEMODIALYSIS; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SELF EXAMINATION; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; CZECH REPUBLIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 74549192022     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903479224     Document Type: Article

References (31)

1. International Diabetes Federation. Diabetes Atlas, 3rd edn. Brussels, Belgium: IDF, 2006
2. Sarol JN, Nicodemus NA, Tan KM, et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin 2005;21:173-183
3. Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006;22:671-681
4. Poolsup N, Suksomboon N, Jiamsathit W. Systematic review of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients. Diabetes Technol Ther 2008;10:S51-66
5. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001;111:1-9
6. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-1763
7. McGeoch G, Moore RA. Self-monitoring of blood glucose in type 2 diabetes: what is the evidence? Diabetes Metab Res Rev 2007;23:423-440
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
9. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
10. Blonde L, Karter AJ. Current evidence regarding the value of self-monitored blood glucose testing. Am J Med 2005;118:20-6S
11. Franciosi M, Pellegrini F, De Berardis G, et al. Self-monitoring of blood glucose in non-insulin-treated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabet Med 2005;22:900-906
12. Davis WA, Bruce DG, Davis TME. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006;29:1764-1770
13. Davis WA, Bruce DG, Davis TM. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia 2007;50:510-555
14. Schnell O, Heinemann L. Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: a never ending story? J Diab Sci Tech 2007;1:614-616
15. Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006;49:271-278
16. Care of diabetics 2007 (annual report), Health Statistics, DM Patients Care 2007. UZIS CR 2008; available at URL:
17. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444
18. Fuller JH, Shipley MJ, Rose G, et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed) 1983;287:867-870
19. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogen-esis of diabetic complications. Diabetologia 2003;46(Suppl 1):M9-16
20. Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol Ther 2008; 10:S72-81
21. Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834
22. Derr R, Garrett E, Stacy GA, et al. Is HbA(1c) affected by glycemic instability? Diabetes Care 2003;26:2728-2733
23. Kolb H., Schneider B, Heinemam L, et al. Type 2 diabetes phenotype and progression is significantly different in if diagnosed before versus after 65 years of age. J Diabetes Sci Technol 2008;2:82-90
24. Schneider B, Martin S, Heinemann L, et al. Interrelations between diabetes therapy, self-monitoring of blood glucose, blood glucose and non-fatal or fatal endpoints in patients with type 2 diabetes-results of a longitudinal cohort study (ROSSO 5). Arzneimittelforschung 2007;57:762-769
25. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians, 2008
26. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care 2009;32:S13-61
27. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005
28. Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoeconom Outcome Res 2005;5:65-79
29. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on Good Research Practices-Budget Impact Analysis. Value Health 2007;10:336-347
30. Brunerova L, Andel M. Calculation of the costs of drugs, medical materials, certain medical procedures and social services for patients with diabetic foot syndrome. Vnitr Lek 2003;49:457-464
31. VZP CR health insurance company of the Czech Republic. Císelník-PZT. Reimbursement list 2009; available at URL: http://www.vzp.cz/cms/internet/ cz/Lekari/Ciselniky